Neurocrine Biosciences, Inc. · NASDAQ:NBIX

Neurocrine Biosciences — Q4 2022 Earnings Presentation

42 slides from Neurocrine Biosciences's earnings presentation, Feb 6, 2023

  1. Slide 1: Advancing Life-Changing Discoveries in Neuroscience

    Advancing Life-Changing Discoveries in Neuroscience Q4 2022 / Year-End Corporate Presentation February 6, 2023 Nasdaq: NBIX

  2. Slide 2: Safe Harbor Statement and Non-GAAP Financial Measures

    Safe Harbor Statement and Non-GAAP Financial Measures In addition to historical facts, this presentation contains forward-looking statements that involve a number of risks and uncertainties. These statements include, but are not limited to, statements related to: the benefits to be derived from our

  3. Slide 3: Well Positioned for Sustained & Long-term Growth

    Well Positioned for Sustained & Long-term Growth 2023 Annual Net * Sales Guidance of ~600,000 are affected by TD in the U.S. $1.67B to $1.77B (70% are undiagnosed) (Tardive Dyskinesia Only) R&D Focus Robust 12 Programs Currently in Mid- to Late-Stage Studies • Neurology • Neuroendocrinology Pipeline

  4. Slide 4: Q4 & FY 2022 Highlights and Future Key Milestones and Activities

    Q4 & FY 2022 Highlights and Future Key Milestones and Activities Q4 2022 and FY Highlights Future Key Milestones and Activities ▪ INGREZZA® (valbenazine) Net Product Sales of over $1.4B with 2023 ~ 260,000 TRx in 2022 ▪ Potential sNDA Approval of Valbenazine for the Treatment of − Represents YoY Sal

  5. Slide 5: Significant Milestones This Year

    Significant Milestones This Year Valbenazine Crinecerfont NBI-921352 NBI-1065846 Chorea in HD Congenital Adrenal Hyperplasia Focal Onset Seizures Anhedonia in MDD PDUFA = August 20th Phase 3 data in Adult and Phase 2 data Phase 2 data Pediatric Studies Selective CRF1 receptor Selective Nav channel G

  6. Slide 6: Multiple Molecules and Mechanisms to Treat Intractable Diseases

    Multiple Molecules and Mechanisms to Treat Intractable Diseases NEUROLOGY NEUROENDOCRINOLOGY SCN8A Chorea in Tardive Focal Onset Developmental Adrenal Huntington Dyskinesia Parkinson’s Endometriosis Uterine Fibroids Insufficiency Seizures (FOS) and Epileptic Disease (HD) Disease FDA APPROVED FDA APP

  7. Slide 7: Strong Pipeline Momentum

    Strong Pipeline Momentum Phase 1 Phase 2 Phase 3 Partner Upcoming Milestones Neurology valbenazine* Chorea in Huntington Disease PDUFA Date = August 20th, 2023 valbenazine* Dyskinetic Cerebral Palsy Registrational Top-Line Data Expected in 2024 Reviewing Full Data Set from Phase 2 Study to NBI-82710

  8. Slide 8: 2022 Annual Financial Summary

    2022 Annual Financial Summary $ Millions, Except Non-GAAP Earnings Per Share Item 2022 2021 Highlights / Comments Revenue $1,489 $1,133 - Product Sales, Net 1,441 1,090 INGREZZA Sales of ~$1.43 Billion - Collaboration Revenue 48 43 Non-GAAP R&D Expense 406 280 Increase Driven by Expanded / Advancing

  9. Slide 9: Q4 2022 Financial Summary

    Q4 2022 Financial Summary $ Millions, Except Non-GAAP Earnings Per Share Item Q4 2022 Q4 2021 Highlights / Comments Revenue $412 $312 Q4 2022 INGREZZA Sales of $399M with Record - Product Sales, Net 405 304 New Patients and Continued Strong Compliance / Persistence Rates for Existing Patients - Coll

  10. Slide 10: 2023 INGREZZA Sales and Operating Expense Guidance

    2023 INGREZZA Sales (TD Indication Only) and Operating Expense Guidance Item ($ Millions) 2022 Actuals 2023 Guidance Range INGREZZA Net Product Sales1 $1,428 $1,670 - $1,770 GAAP R&D Expense2 $464 $550 - $580 Non-GAAP R&D Expense3 $406 $495 - $525 GAAP SG&A Expense $753 $850 - $870 Non-GAAP SG&A Exp

  11. Slide 11: Corporate Sustainability

    Corporate Sustainability Our Purpose: Relieve Suffering for People with Great Needs, but Few Options Adhere to the highest Invest in our people Minimize our impact product quality and and communities on the environment safety standards Comprehensive Quality Industry-leading employee Improving profit

  12. Slide 12: Our Medicines, Our Patients

    © NEYROCRINE Our Medicines, Our Patients

  13. Slide 13: Commercial Products Fueling Pipeline Investment

    Commercial Products Fueling Pipeline Investment In the U.S. * ‡ And now… TARDIVE DYSKINESIA ENDOMETRIOSIS For pediatric patients in the ‡ U.S. and EU † ADRENAL INSUFFICIENCY PARKINSON'S DISEASE UTERINE FIBROIDS *Mitsubishi Tanabe Pharma Corporation (MTPC) has commercialization rights in Japan and ot

  14. Slide 14: INGREZZA

    INGREZZA (valbenazine) capsules NEUROCRINE BIOSCIENCES

  15. Slide 15: INGREZZA Quarterly Net Sales Performance

    INGREZZA Quarterly Net Sales Performance ($MM) $450 7th Sequential Period of Growth $399 $400 $376 $350 $350 $301 $303 $300 $287 $265 $250 $230 $200 Q1 '21 Q2 '21 Q3 '21 Q4 '21 Q1 '22 Q2 '22 Q3 '22 Q4 '22 15

  16. Slide 16: Substantial Impact on TD Patients and Care Partners

    Substantial Impact on TD Patients and Care Partners Movement disorder caused by prolonged use of antipsychotics and anti-nausea medications Uncontrollable, abnormal and repetitive movements >50% of patients experience meaningful emotional, social and psychological impact* Job Performance Low Self-Wo

  17. Slide 17: Nascent TD Market Presents Significant Opportunity

    Nascent TD Market Presents Significant Opportunity Approximately 30% of TD Patients Diagnosed E S T I M AT E D T O A F F E C T ~600,000 ✓ Only half of diagnosed patients receive treatment for TD with a VMAT2 inhibitor like INGREZZA people in the U.S. ~30% TD Diagnosed Increasing Antipsychotic Prescr

  18. Slide 18: Driving Long-Term Growth for INGREZZA

    Driving Long-Term Growth for INGREZZA Salesforce and distribution expansion INGREZZA and ONGENTYS offering greater access to neurology practices Investing in telemedicine capabilities Recommends patients with TD associated with antipsychotic therapy be treated with a VMAT2 inhibitor Patient outreach

  19. Slide 19: ONGENTYS Is the 1st and Only FDA-Approved Once-Daily COMT Inhibitor

    ONGENTYS Is the 1st and Only FDA-Approved Once-Daily COMT Inhibitor for Parkinson’s Disease Provides Significant Reduction of Daily “Off” Time; Increase in Good “On” Time • Add-on treatment to levodopa/carbidopa prolongs clinical effects • One capsule, once a day treatment • Helps patients achieve m

  20. Slide 20: Neurology Pipeline

    © NEVROCRINE Neurology Pipeline

  21. Slide 21: sNDA for Valbenazine for Chorea in Huntington Disease Accepted by FDA

    Supplemental New Drug Application for Valbenazine for the Treatment of Chorea in Huntington Disease Accepted by FDA Valbenazine* Simple once-a-day treatment targeted for symptom control of chorea movements Safety profile consistent with and supported by extensive safety data in tardive dyskinesia In

  22. Slide 22: Valbenazine: Registrational Program in Dyskinetic Cerebral Palsy

    Valbenazine*: Registrational Program in Dyskinetic Cerebral Palsy Dyskinetic Cerebral Palsy (DCP) A form of cerebral palsy (CP) that affects ~15% of the approximately 500,000 to 1M people in the U.S. diagnosed with the disease. Can result in a range of developmental delays, physical difficulties and

  23. Slide 23: NBI-921352: Selective Nav1.6 Inhibitor in Ongoing Phase 2 Studies

    NBI-921352*: Selective Nav 1.6 Inhibitor in Ongoing Phase 2 Studies With Top-Line Data Expected in FOS in 2H 2023 Adult Focal Onset Seizures (FOS) Background SCN8A-DEE Background Also referred to as partial-onset seizures, Rare pediatric epilepsy with occurrence of these are the most common form of

  24. Slide 24: Neuroendocrinology Pipeline

    Neuroendocrinology Pipeline

  25. Slide 25: Classic Congenital Adrenal Hyperplasia (CAH)

    Classic Congenital Adrenal Hyperplasia (CAH) Rare Genetic Disorder Enzyme deficiency & reduced cortisol levels and excess androgen levels U.S. ~30,000* Europe ~50,000* Complex and Treatment Options Highly Stagnant for 60 Years Variable • Hormone replacement Symptoms • Do not address underlying issue

  26. Slide 26: Congenital Adrenal Hyperplasia Disease Mechanism

    Congenital Adrenal Hyperplasia Disease Mechanism Normal Homeostasis CAH Patients 26

  27. Slide 27: Crinecerfont Potentially Meets Challenges of the Standard of Care

    Crinecerfont* Potentially Meets Challenges of the Standard of Care Overtreatment Hypercortisolism Overtreatment Insulin Resistance Undertreatment Hypercortisolism Central Obesity Hyperandrogenism Osteoporosis Potentially Fatal Adrenal Crisis Insulin Resistance Impaired Glucose Tolerance CRINECERFONT

  28. Slide 28: Potential Paradigm Shift in the Treatment of CAH

    Potential Paradigm Shift in the Treatment of CAH With Top-Line Results Expected For Each Study in 2H 2023 Crinecerfont* Phase 3 Global Adult Registrational Study Ongoing ENROLLMENT Phase 3 Global Pediatric Registrational Study Ongoing COMPLETE Potent Orally Active Selective Well-Tolerated *Crinecerf

  29. Slide 29: Neuropsychiatry Pipeline

    (5) NEUROCRINE BIOSCIENCES

  30. Slide 30: Valbenazine: Registrational Program in Adjunctive Treatment of Schizophrenia

    Valbenazine*: Registrational Program in Adjunctive Treatment of Schizophrenia With Top-Line Date in 1st Study in 2024 Adjunctive Treatment of Schizophrenia (ATS) Schizophrenia is one of the leading causes of disability worldwide, affecting up to 3.5M people in the U.S. alone. A serious, chronic ment

  31. Slide 31: Potential First-in-Class Neuropsychiatry Programs

    Potential First-in-Class Neuropsychiatry Programs Takeda Collaborations Ongoing Clinical Programs in Phase 2 Studies Clinical Programs in Phase 2 Studies NBI-1065846* Anhedonia in Major Depressive Disorder Top-line Data Expected in 2H 2023 Inadequate Response to Treatment in NBI-1065845* Major Depre

  32. Slide 32: NBI-1065846: GPR139 Agonist

    NBI-1065846*: GPR139 Agonist Anhedonia in Major Depressive Disorder NBI-1065846 260 million+ people worldwide are Potent first-in-class investigational GPR139 agonist • Once weekly affected by major depressive disorder • Potential adjunctive treatment (MDD). GPR139 is an orphan receptor in the haben

  33. Slide 33: NBI-1065845: AMPA Potentiator

    NBI-1065845*: AMPA Potentiator Inadequate Response to Treatment NBI-1065845 in Major Depressive Disorder (MDD) Potent first-in-class AMPA potentiator ~1/3 of the 16 million+ people in the • Once daily U.S. who live with MDD do not respond • Potential adjunctive treatment to available antidepressants

  34. Slide 34: Luvadaxistat: D-Amino Acid Oxidase (DAAO) Inhibitor

    Luvadaxistat*: D-Amino Acid Oxidase (DAAO) Inhibitor Cognitive Impairment Associated with Luvadaxistat Schizophrenia (CIAS) Affects approximately 80% of the 3.5 Potent first-in-class DAAO inhibitor • Once daily million people in the U.S. diagnosed • No titration requirement with schizophrenia Hypofu

  35. Slide 35: Developing Novel Muscarinic Receptor Agonist Portfolio

    Developing Novel Muscarinic Receptor Agonist Portfolio Neurocrine Biosciences Advancing Muscarinic Portfolio Clinical studies, include: ➢ Initiated Phase 2 placebo-controlled study of NBI-1117568*, a selective M4 agonist, as a potential treatment for schizophrenia ✓ NBI-1117568 offers the potential

  36. Slide 36: Well Positioned for Sustained & Long-term Growth

    Well Positioned for Sustained & Long-term Growth 2023 Annual Net * Sales Guidance of ~600,000 are affected by TD in the U.S. $1.67B to $1.77B (70% are undiagnosed) (Tardive Dyskinesia Only) R&D Focus Robust 12 Programs Currently in Mid- to Late-Stage Studies • Neurology • Neuroendocrinology Pipeline

  37. Slide 37: GAAP to Non-GAAP Reconciliations

    GAAP to Non-GAAP Reconciliations neurocrine.com

  38. Slide 38: Condensed Consolidated Statements of Operations

    NEUROCRINE BIOSCIENCES NEUROCRINE BIOSCIENCES, INC. CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (in millions, except per share data) Revenues: Product sales, net Collaboration revenue Total revenues Operating expenses: Cost of revenues Research and development Acquired in-process research and de

  39. Slide 39: Condensed Consolidated Balance Sheets

    NEUROCRINE BIOSCIENCES, INC. CONDENSED CONSOLIDATED BALANCE SHEETS (unaudited) December 31, December 31, (in millions) 2022 2021 Cash, cash equivalents and debt securities available-for-sale $ 989.3 $ 711.3 Other current assets 464.2 261.5 Total current assets 1,453.5 972.8 Deferred tax assets 305.9

  40. Slide 40: Reconciliation of GAAP to Non-GAAP Financial Results

    NEUROCRINE BIOSCIENCES NEUROCRINE BIOSCIENCES, INC. RECONCILIATION OF GAAP TO NON-GAAP FINANCIAL RESULTS (unaudited) Three Months Ended Twelve Months Ended December 31, December 31, (Gn millions, except per share data) 2022 2021 2022 2021 GAAP net income (loss) $ $90 $ (73) $1545 $ 39.6 Adjustments:

  41. Slide 41: Reconciliation of GAAP to Non-GAAP Expenses

    NEUROCRINE BIOSCIENCES NEUROCRINE BIOSCIENCES, INC. RECONCILIATION OF GAAP TO NON-GAAP EXPENSES (unaudited) Three Months Ended ‘Twelve Months Ended December 31, December 31, (x millions) 2022 2021 2032 2021 GAAP cost of revenues $ 77 $ 41 $ 232 $ 143 Adjustments: Non-cash amortization related to acq

  42. Slide 42: Advancing Life-Changing Discoveries in Neuroscience

    Advancing Life-Changing Discoveries in Neuroscience Q4 2022 / Year-End Corporate Presentation February 6, 2023 Nasdaq: NBIX

Neurocrine Biosciences — Q4 2022 Earnings Presentation on 6ix